Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Joon Seok Bang & Jong Hyuk Lee. (2021) The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways. Expert Opinion on Orphan Drugs 9:4, pages 105-112.
Read now
Read now
Jason R Guertin, Dominic Mitchell, Farzad Ali & Jacques LeLorier. (2015) Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug. ClinicoEconomics and Outcomes Research 7, pages 497-503.
Read now
Read now
Pieter Dylst, Arnold Vulto & Steven Simoens. (2015) Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 33-42.
Read now
Read now
Pieter Dylst, Arnold G Vulto & Steven Simoens. (2014) Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability. Expert Review of Pharmacoeconomics & Outcomes Research 14:3, pages 345-353.
Read now
Read now
Brian Godman, Iain Bishop, Alexander E Finlayson, Stephen Campbell, Hye-Young Kwon & Marion Bennie. (2013) Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Review of Pharmacoeconomics & Outcomes Research 13:4, pages 469-482.
Read now
Read now
Jessica Fraeyman, Guido Van Hal, Brian Godman & Philippe Beutels. (2013) The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Review of Pharmacoeconomics & Outcomes Research 13:1, pages 141-151.
Read now
Read now
Pieter Dylst, Arnold Vulto & Steven Simoens. (2013) Demand-side policies to encourage the use of generic medicines: an overview. Expert Review of Pharmacoeconomics & Outcomes Research 13:1, pages 59-72.
Read now
Read now
Anna Bucsics, Brian Godman, Thomas Burkhardt, Manuela Schmitzer & Rickard E Malmström. (2012) Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert Review of Pharmacoeconomics & Outcomes Research 12:6, pages 809-819.
Read now
Read now
Cara Usher & Michael Barry. (2012) A reference pricing system for Ireland. Expert Review of Pharmacoeconomics & Outcomes Research 12:6, pages 675-677.
Read now
Read now
Articles from other publishers (23)
Serena Perna, Agnese Cangini, Roberto Marini, Maria Alessandra Guerrizio, Roberto Da Cas, Giuseppe Traversa & Francesco Trotta. (2022) Dynamics of price competition in Italian pharmaceutical off-patent market. Frontiers in Medicine 9.
Crossref
Crossref
Marcin Czech, Aleksandra Baran-Kooiker, Kagan Atikeler, Maria Demirtshyan, Kamilla Gaitova, Malwina Holownia-Voloskova, Adina Turcu-Stiolica, Coen Kooiker, Oresta Piniazhko, Natella Konstandyan, Olha Zalis'ka & Jolanta Sykut-Cegielska. (2020) A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries. Frontiers in Public Health 7.
Crossref
Crossref
Sabine Vogler, Guillaume Dedet & Hanne Bak Pedersen. (2019) Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries. Applied Health Economics and Health Policy 17:6, pages 803-816.
Crossref
Crossref
David Granlund & Mats A. Bergman. (2018) Price competition in pharmaceuticals – Evidence from 1303 Swedish markets. Journal of Health Economics 61, pages 1-12.
Crossref
Crossref
R. L. Rovbel. (2018) Analyzing the Problems and Opportunities of Reference Pricing for the Use by State Government and Local Self-Government Bodies in Procurement Activities and Housing Development. Management Science 8:2, pages 44-51.
Crossref
Crossref
Seda Kumru & Mehmet Top. (2018) Pricing and reimbursement of generic pharmaceuticals in Turkey: Evaluation of hypertension drugs from 2007 to 2013. Health Policy and Technology 7:2, pages 182-193.
Crossref
Crossref
Nika Marđetko & Mitja Kos. (2017) Introduction of therapeutic reference pricing in Slovenia and its economic consequences. The European Journal of Health Economics 19:4, pages 571-584.
Crossref
Crossref
Mohamed Azmi Hassali & Zhi Yen Wong. 2018. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries
197
210
.
F. Antoñanzas, C. A. Juárez-Castelló & R. Rodríguez-Ibeas. (2017) Endogenous versus exogenous generic reference pricing for pharmaceuticals. International Journal of Health Economics and Management 17:4, pages 413-432.
Crossref
Crossref
Ji Haeng Heo, Karen L. Rascati & Eui-Kyung Lee. (2017) Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea. Value in Health Regional Issues 12, pages 7-19.
Crossref
Crossref
Panagiotis Petrou & Sotiris Vandoros. (2016) Pharmaceutical price comparisons across the European Union and relative affordability in Cyprus. Health Policy and Technology 5:4, pages 350-356.
Crossref
Crossref
Hanna Koskinen, Hennamari Mikkola, Leena K. Saastamoinen, Elina Ahola & Jaana E. Martikainen. (2015) Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland. Value in Health 18:8, pages 1105-1112.
Crossref
Crossref
Andrew Lofts Gray & Fatima Suleman. (2015) The relevance of systematic reviews on pharmaceutical policy to low- and middle-income countries. International Journal of Clinical Pharmacy 37:5, pages 717-725.
Crossref
Crossref
Panagiotis Petrou & Sotiris Vandoros. (2015) Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment. Health Policy 119:5, pages 563-568.
Crossref
Crossref
Hanna Koskinen, Elina Ahola, Leena K Saastamoinen, Hennamari Mikkola & Jaana E Martikainen. (2014) The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland. Health Economics Review 4:1.
Crossref
Crossref
Brian Godman, Max Petzold, Kathleen Bennett, Marion Bennie, Anna Bucsics, Alexander E Finlayson, Andrew Martin, Marie Persson, Jutta Piessnegger, Emanuel Raschi, Steven Simoens, Corinne Zara & Corrado Barbui. (2014) Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Medicine 12:1.
Crossref
Crossref
Christian Selmer, Morten Lamberts, Søren Lund Kristensen, Lene Mia von Kappelgaard, Lars Køber, Gunnar Hilmar Gislason & Christian Torp-Pedersen. (2014) Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies. Pharmacoepidemiology and Drug Safety 23:12, pages 1281-1287.
Crossref
Crossref
Thirimon Moe-Byrne, Duncan Chambers, Melissa Harden & Catriona McDaid. (2014) Behaviour change interventions to promote prescribing of generic drugs: a rapid evidence synthesis and systematic review. BMJ Open 4:5, pages e004623.
Crossref
Crossref
Suzanne Dunne, Bill Shannon, Colum Dunne & Walter Cullen. (2013) A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacology and Toxicology 14:1.
Crossref
Crossref
Dahlia Y. Balaban, Irfan A. Dhalla, Michael R. Law & Chaim M. Bell. (2013) Private Expenditures on Brand Name Prescription Drugs after Generic Entry. Applied Health Economics and Health Policy 11:5, pages 523-529.
Crossref
Crossref
Steven Simoens, Kristien De Bruyn, Jamilette Miranda, Marion Bennie, Rickard E. Malmström & Brian Godman. (2013) Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future. Journal of Pharmaceutical Health Services Research 4:3, pages 173-181.
Crossref
Crossref
L.M. Niëns & W.B.F. Brouwer. (2013) Measuring the affordability of medicines: Importance and challenges. Health Policy 112:1-2, pages 45-52.
Crossref
Crossref
Susan E. Tett, Ingrid Sketris, Charmaine Cooke, Sander Veldhuyzen van Zanten & Nadia Barozzi. (2013) Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada. Pharmacoepidemiology and Drug Safety 22:7, pages 735-743.
Crossref
Crossref